Opinion
21-1070
01-03-2022
NOVARTIS PHARMACEUTICALS CORPORATION, Plaintiff-Appellee v. ACCORD HEALTHCARE, INC., AUROBINDOPHARMA LTD., AUROBINDO PHARMA USA, INC., DR. REDDY'S LABORATORIES, INC., DR. REDDY'SLABORATORIES, LTD., EMCUREPHARMACEUTICALS LTD., HERITAGEPHARMACEUTICALS INC., GLENMARKPHARMACEUTICALS INC., USA, GLENMARKPHARMACEUTICALS LIMITED, HETERO USA, INC., HETERO LABS LIMITED UNIT-V, HETEROLABS LIMITED, MYLAN PHARMACEUTICALS, INC., PRINSTON PHARMACEUTICAL INC., STRIDES GLOBAL PHARMA PRIVATE LIMITED, STRIDES PHARMA, INC., TORRENT PHARMAINC., TORRENT PHARMACEUTICALS LTD., ZYDUS PHARMACEUTICALS (USA) INC., CADILAHEALTHCARE LTD., APOTEX INC., APOTEXCORP., SUN PHARMACEUTICAL INDUSTRIES, LTD., SUN PHARMACEUTICAL INDUSTRIES INC., SUN PHARMA GLOBAL FZE, Defendants HEC PHARM CO., LTD., HEC PHARM USA INC., Defendants-Appellants
This order is nonprecedential.
Errata Filed Date: January 4, 2022
ERRATA 1
Please make the following change:
Page 2, line 7 (majority opinion): the issuance date of "January 3, 2021" is changed to "January 3, 2022". 2